Protocol Ledger

NCT07693959 · Phase III · RECRUITING

Neoadjuvant RC48 Plus Gemcitabine in HER2-Expressing MIBC

Interventional Phase III clinical trial protocol NCT07693959 sponsored by Zhiquan Hu in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-07-01 Enrollment: 170 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07693959
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)170 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07693959
Protocol FieldVerified Registry Value
NCT IdentifierNCT07693959
Consolidated Lead SponsorZhiquan Hu
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment170 participants (ESTIMATED)
Registered Start Date2026-07-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI